Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Gercek Can¹, Ediz Dalkılıc², Yavuz Pehlivan², Soner Senel³, Servet Akar⁴, Dilek Solmaz⁵, Suleyman Serdar Koca⁶, Nevsun İnanc⁷, Pamir Atagunduz⁷, Ayten Yazıcı⁸, Ayse Cefle⁸, Berna Goker⁹, Berrin Zengin¹, Sadettin Uslu¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Uludag University Faculty of Medicine Rheumatology, bursa, Turkey, ³Rheumatology, Erciyes University Faculty of Medicine Rheumatology, kayseri, Turkey, ⁴Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁶Rheumatology, Fırat University Faculty of Medicine, elazıg, Turkey, ⁷Rheumatology, Marmara University Faculty of Medicine Rheumatology, istanbul, Turkey, ⁸Rheumatology, Kocaeli University Faculty of Medicine Rheumatology, kocaeli, Turkey, ⁹Rheumatology, Gazi Universty of Fakulty of Medicine, ankara, Turkey, ¹⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ¹¹Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…
Abstract Number: 2002 • 2017 ACR/ARHP Annual Meeting
Baseline 18F Sodium Fluoride Uptake of Vertebral Bodies but Not Vertebral Corners on Positron Emission Tomography Is Associated with Changes in Bone Mineral Density at Lumbar Vertebrae in Ankylosing Spondylitis: A 1-Year Longitudinal Study
Seung-Geun Lee¹, Keunyoung Kim², Seong-Min Kweon³, Eun-Kyoung Park⁴, Yun-Kyung Kim⁵ and Geun-Tae Kim⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ²Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁵Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁶Kosin University College of Medicine, Busan, Korea, Republic of (South)
Background/Purpose: 18F sodium fluoride (NaF) positron emission tomography (PET) allows quantitative assessment of osteoblastic bone synthesis in specific skeletal sites. Previous studies showed that increased…
Abstract Number: 2882 • 2017 ACR/ARHP Annual Meeting
IgG Galactosylation Status Combined with MYOM2 SNP Precisely Predicts Anti-TNF Response in Ankylosing Spondylitis
Jing Liu¹, Shifang Ren², Zhenmin Niu¹, Qi Zhu³, Wei Wan⁴, Jing Han², Yanyun Ma⁵, Weilin Pu⁶, Yuan Li¹, Xia Xu⁴, Yi Wang⁵, Dongbao Zhao⁴, Hui Zhang⁷, Feng Qian⁵, Xiaodong Zhou⁸, John D. Reveille⁹, Li Jin^1,10, Dong-yi He³, Hejian Zou^11,12, Jianxin Gu² and Jiucun Wang^10,12,13, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²Department of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research Ministry of Public Health, School of Basic Medical Sciences, Fudan University, Shanghai, China, ³Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ⁴Department of Rheumatology and Immunology, Changhai Hospital, Shanghai, China, ⁵Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, ⁶State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences,, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China, ⁷School of Life Sciences, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ⁸Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹University of Texas McGovern Medical School, Houston, TX, ¹⁰Fudan-Taizhou Institute of Health Sciences, Taizhou, China, ¹¹Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ¹²Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China, ¹³State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, CN
Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated inflammatory disorder of spine and sacroiliac joints, which could lead to bony fusion of vertebral joints. TNF-blockers have…
Abstract Number: 1000 • 2017 ACR/ARHP Annual Meeting
Use of Mutual Information Theory in Development and Refinement of a Predictive Model for Early Identification of Ankylosing Spondylitis
Atul A. Deodhar¹, Cody Garges², Oodaye Shukla², Theresa Arndt², Tara Grabowsky² and Yujin Park³, ¹Oregon Health & Science University, Portland, OR, ²HVH Precision Analytics, LLC, King of Prussia, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Delayed diagnosis and treatment of ankylosing spondylitis (AS) contribute to the economic, physical and psychological burden on patients and their caregivers. The objective of…
Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Mireia Moreno¹, Caridad Pontes², Ferran Torres³, Agusti Sellas-Fernandez⁴, Miriam Almirall⁵, Juan Carlos Torre-Alonso⁶, Teresa Clavaguera⁷, Carlos Rodriguez-Lozano⁸, Luis Francisco Linares⁹, Ana Urruticoechea-Arana¹⁰, Eduardo Collantes-Estevez¹¹, Rosa Morla¹², Delia Reina¹³, Eduardo Cuende¹⁴, Pedro Zarco¹⁵, Cruz Fernandez-Espartero¹⁶, Rosario García-Vicuña¹⁷, Jesus Sanz¹⁸, Xavier Juanola¹⁹, Antoni Vallano²⁰, Francisco J Blanco²¹, Raimon Sanmarti²², Gonzalo Calvo²³, Cristina Avendaño²⁴, Eugenio De Miguel²⁵, Roser Vives²⁶, Raul Veroz Gonzalez²⁷, Carlos Alberto Montilla-Morales²⁸ and Jordi Gratacos-Masmitja²⁹, ¹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ²Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁵Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, ⁸Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, ⁹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁰Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹¹Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ¹²Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵H Fundación Alcorcón, Alcorcón, Spain, ¹⁶Rheumatology, Hospital de Mostoles, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁰Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, ²¹Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²²Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ²³Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, ²⁴Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, ²⁵Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²⁶Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ²⁷Hospital de Mérida, Mérida, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
Abstract Number: 2241 • 2017 ACR/ARHP Annual Meeting
Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors
Jing Xue¹, Wenqiang Fan², Hua Wei³, Jing Yang⁴, Hui Song⁵, Hongbin Li⁶, Hongzhi Wang⁷, Xinwang Duan⁸, Zhenchun Zhang⁹, Jianlin Huang¹⁰, Yasong Li¹¹, Jian Ding¹², Xiaofei Shi¹³, Miaojia Zhang¹⁴, Zhenbiao Wu¹⁵, Cundong Mi¹⁶, Fei Xiao¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁷, Rui Bai¹⁷, Yan Bu¹⁷ and Huaxiang Wu¹⁸, ¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁵Beijing Jishuitan Hospital, Beijing, China, ⁶The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁹People's Hospital of Linyi, Shandong, Linyi, China, ¹⁰Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ¹¹Zhejiang Provincal People's Hospital, Hangzhou, China, ¹²Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, China, ¹³The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁴Department of Rheumatology and Immunology, Jiangsu Province Hospital, Nanjing, China, ¹⁵The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, China, ¹⁶The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, ¹⁷Gothic Internet Technology Corporation, Shanghai, China, ¹⁸The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Background/Purpose: This study is to evaluate pattern shifts and outcome trends of treat-to-target (T2T) under standard of care in ankylosing spondylitis (AS) patients with interactive…
Abstract Number: 1001 • 2017 ACR/ARHP Annual Meeting
Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Theresa Hunter¹, Krista Schroeder², Sarah Al Sawah² and David Sandoval Calderon², ¹Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The primary goals of treating Ankylosing Spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention…
Abstract Number: 1539 • 2017 ACR/ARHP Annual Meeting
High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Helena Marzo-Ortega², Clarence Legerton³, Joachim Sieper⁴, Ricardo Blanco⁵, Martin Cohen⁶, Evie Maria Delicha⁷, Susanne Rohrer⁷ and Hanno Richards⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ³Low Country Rheumatology, Articularis Healthcare, Charleston, SC, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶McGill University, Montreal, QC, Canada, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we…
Abstract Number: 2496 • 2017 ACR/ARHP Annual Meeting
The Disease Course in Daily Clinical Practice in Radiographic and Non-Radiographic Axial Spondyloarthritis Patients; One-Year Follow-up Results of National-Subgroup of a Worldwide Observational Cohort Study
Servet Akar¹, Ilhan Sezer², Yasemin Yumusakhuylu³, Ayşen Akinci⁴, Kemal Erol⁵, Kenan Akgun⁶, Hatice Bodur⁷, Sebnem Ataman⁸, Omer Kuru⁹, Meltem Melikoglu¹⁰, Murat Karkucak¹¹, Nazli Derya Bugdayci¹², Duygu Ersozlu Bakirli¹³, Murat Birtane¹⁴, Tuncay Duruoz¹⁵, Sukran Erten¹⁶, Ediz Dalkilic¹⁷, Gülay KINIKLI¹⁸, Cemal Bes¹⁹, Ahmet Omma²⁰ and Aylin Rezvani²¹, ¹Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ²Physical Medicine and Rehabilitation-Rheumatology, Antalya Training and Research Hospital, Antalya, Turkey, ³Department of Physical Medicine and Rehabilitation, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ⁴Hacettepe University Medical School Department of Physical Medicine and Rehabilitation, Ankara, Turkey, ⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, ⁶Department of Physical Medicine and Rehabilitation, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ⁷Department of Physical Medicine and Rehabilitation, Ankara Numune Training and Research Hospital, Ankara, Turkey, ⁸Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ⁹Department of Physical Medicine and Rehabilitation, 19 Mayis University, Faculty of Medicine, Samsun, Turkey, ¹⁰Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ataturk University School of Medicine, Erzurum, Turkey, ¹¹Department of Physical Medicine and Rehabilitation, Karadeniz Technical University, Faculty of Medicine, Farabi Hospital, Trabzon, Turkey, ¹²Department of Physical Medicine and Rehabilitation, Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, Istanbul, Turkey, ¹³Department of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey, ¹⁴Department of Physical Medicine and Rehabilitation, Trakya University Faculty of Medicine, Edirne, Turkey, ¹⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University, Faculty of Medicine, Pendik Training and Research Hospital, Istanbul, Turkey, ¹⁶Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ¹⁷Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ¹⁸Department of Rheumatology, Ankara University, Faculty of Medicine, Department of Internal Medicine, Rheumatology, Ankara, Turkey, ¹⁹Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ²⁰Department of Internal Medicine, Division of Rheumatology, Ankara Numune Training and Research Hospital, Ankara, Turkey, ²¹Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The natural history of axial spondyloarthritis (axSpA) has not been clearly established yet. The aim of this study is to evaluate the natural course…
Abstract Number: 1234 • 2017 ACR/ARHP Annual Meeting
How Machine Learning Statistics Can Change the Game of Data Analysis in Rheumatology: The Example a Study with 170 Patients with Rheumatoid Arthritis (ra) or Axial Spondyloarthritis (axspa)
Frédéric Guyard¹, Laure Gossec², Didier Leroy³, Thomas Lafargue¹, Michel Seiler³, Charlotte Jacquemin⁴, Anna Molto⁵, Jeremie Sellam⁶, Violaine Foltz⁴, Frédérique Gandjbakhch⁴, Christophe Hudry⁷, Stéphane Mitrovic⁴, Bruno Fautrel⁴ and Herve Servy⁸, ¹IMT, Orange, Nice, France, ²UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ³Healthcare, Orange, Paris, France, ⁴UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷AP-HP Hôpital Cochin, Paris, France, ⁸e-health services, Sanoia, Gemenos, France
Background/Purpose: A link between flares and physical activity would confirm the objective consequences of flares. In the ActConnect study of patients with RA or axSpA,…
Abstract Number: 1540 • 2017 ACR/ARHP Annual Meeting
Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine
Seung Min Son, Orthopaedic surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of (South)
Background/Purpose: There are many studies about impact of TNF-inhibitors on radiographic progression but little data are available on the relationship between treatment agents and sagittal…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 1473 • 2017 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Interim Results from a Non-Interventional Trial in Germany
Klaus Krüger¹, Sven Remstedt², Astrid Thiele³ and Ines Klaudius⁴, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheuma Praxis Berlin, Berlin, Germany, ³Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁴MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In Germany no prospective data are available for Golimumab (GLM) in patients with RA, AS and PsAregarding outcomes evaluating work productivity and activity in…
Abstract Number: 1546 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
Walter P. Maksymowych¹, Ernest Choy², Yusuf Yazici³, Jessica A. Walsh⁴, Howard Thom⁵, Chrysostomos Kalyvas⁶, Todd Fox⁷, Kunal Gandhi⁸ and Steffen Jugl⁷, ¹Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ²Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ³School of Medicine, New York University School of Medicine, New York City, NY, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, ⁶Real World Strategy and Analytics, MAPI Group, Houten, Netherlands, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: No data are available from head-to-head randomized controlled trials (RCTs) between secukinumab 150mg (SEC; an anti-IL-17A) and golimumab 50mg (GOL; a TNF inhibitor [TNFi])…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].